Diabetic Retinopathy Treatment in India & UAE — Expert Retinal Care
Diabetic retinopathy treatment in India from $800. Laser photocoagulation, anti-VEGF injections & vitrectomy by leading retinal specialists. Prevent blindness. Consult GAF Healthcare today.
Estimated cost: $800 – $3,000 · Average stay: 2–4 days
Diabetic retinopathy is the leading cause of avoidable vision loss in working-age adults worldwide. It develops when persistently elevated blood glucose damages the tiny blood vessels of the retina, causing them to leak fluid, develop abnormal new vessels, and eventually scar — threatening the delicate retinal tissue responsible for central and peripheral vision. Globally, over 100 million people have diabetic retinopathy; in India alone, it affects an estimated 18 million diabetics.
The good news is that diabetic retinopathy is largely preventable with good diabetes control and detectable in its treatable stages with annual retinal screening. When detected early and treated appropriately, the vast majority of vision-threatening diabetic retinopathy can be stabilised or improved, preserving useful vision for life. The challenge is awareness and access — too many patients present too late, when irreversible damage has already occurred.
India has built a substantial and internationally respected infrastructure for diabetic eye disease, driven by the country's massive burden of type 2 diabetes (the world's second largest). Aravind Eye Hospital's DR screening programme (screening over 500,000 diabetics per year across Tamil Nadu using trained ophthalmic technicians and telemedicine), LV Prasad Eye Institute's diabetic retinopathy initiative, and the retinal departments of leading private hospitals in Mumbai, Chennai, and Delhi offer screening, fluorescein angiography, OCT, laser photocoagulation, anti-VEGF injections, and vitreoretinal surgery for all stages of diabetic eye disease.
For patients from the UAE, Russia, the UK, and other countries seeking comprehensive, affordable diabetic eye care — including patients who need vitrectomy for advanced vitreous haemorrhage or tractional retinal detachment — India offers world-class retinal expertise at 70–80% below Western costs.
Stages and Types of Diabetic Retinopathy
Diabetic retinopathy progresses through recognised stages. Non-proliferative diabetic retinopathy (NPDR) encompasses the early stages in which the retinal blood vessels show structural damage (microaneurysms, intraretinal haemorrhages, venous beading, intraretinal microvascular abnormalities, IRMA) but new vessel growth has not yet begun. NPDR is classified as mild, moderate, or severe based on the extent of these changes.
Proliferative diabetic retinopathy (PDR) is the advanced, sight-threatening stage in which the ischaemic retina produces vascular endothelial growth factor (VEGF) — a potent signal for new blood vessel growth. These new vessels (neovascularisation) grow on the retinal surface and vitreous face, are fragile, and bleed easily into the vitreous (vitreous haemorrhage), causing sudden blurring or complete loss of vision. Fibrovascular proliferations can contract and cause tractional retinal detachment. PDR requires urgent treatment.
Diabetic macular oedema (DMO) is thickening and fluid accumulation within the macula — the central retinal area responsible for reading and fine detail — caused by leakage from damaged retinal capillaries. DMO can occur at any stage of diabetic retinopathy and is the most common cause of vision loss in diabetics. It is classified as centre-involving (CI-DMO — involving the fovea, causing central vision loss) or non-centre-involving. CI-DMO is the primary target of anti-VEGF therapy.
Clinically significant macular oedema (CSMO) is a traditional classification (replaced in modern guidelines by OCT-defined CI-DMO) denoting oedema involving or threatening the foveal centre and traditionally treated with focal or grid laser. Modern treatment now prioritises anti-VEGF injections for CI-DMO before considering laser.
Treatment Options for Diabetic Retinopathy
Treatment of diabetic retinopathy is directed at two goals: reducing the stimulus for new vessel growth (by treating retinal ischaemia with laser or anti-VEGF agents) and reducing macular fluid (with anti-VEGF injections or laser). Systemic diabetes control is the fundamental long-term treatment — every 1% reduction in HbA1c reduces the risk of retinopathy progression by approximately 35%.
Anti-VEGF Intravitreal Injections are the first-line treatment for centre-involving diabetic macular oedema (CI-DMO) and for active proliferative diabetic retinopathy with vitreous haemorrhage. Anti-VEGF agents (ranibizumab/Lucentis, bevacizumab/Avastin, aflibercept/Eylea, and brolucizumab/Beovu) are injected into the vitreous cavity through the pars plana under topical anaesthetic, using a very fine needle. The injection takes seconds and is well tolerated. Injections are typically given monthly for the first three to six months, then on an as-needed or treat-and-extend protocol thereafter. In India, all approved anti-VEGF agents are available; off-label bevacizumab (compounded for intravitreal use) offers a significantly lower per-injection cost.
Laser Photocoagulation remains an important tool, particularly for NPDR and PDR management. Panretinal photocoagulation (PRP) applies hundreds of laser burns across the peripheral retina, destroying ischaemic tissue and reducing the VEGF stimulus — preventing or causing regression of new blood vessels. PRP is applied in one to three sessions in an outpatient setting. Focal and grid laser treats specific leaking microaneurysms and areas of macular oedema (increasingly superseded by anti-VEGF therapy for CI-DMO but still used for focal non-centre-involving oedema).
Intravitreal Steroid Implants (dexamethasone implant/Ozurdex; fluocinolone acetonide implant/Iluvien) are options for patients with refractory DMO who have had an inadequate response to anti-VEGF therapy or who are pseudophakic (after cataract surgery). They provide sustained steroid release over 3–6 months (Ozurdex) or 3 years (Iluvien). Elevation of IOP and acceleration of cataract are the main side effects.
Vitrectomy is required for: non-clearing vitreous haemorrhage (persistent blood in the vitreous cavity obscuring vision, not clearing after 1–3 months of observation); tractional retinal detachment threatening or involving the macula; and combined tractional-rhegmatogenous retinal detachment. The vitrectomy removes the haemorrhagic vitreous, peels tractional membranes from the retinal surface, and flattens the retina, typically with anti-VEGF pre-treatment 1 week before surgery to reduce intraoperative bleeding.
Procedure Steps
- Full retinal assessment: fundus photography, fluorescein angiography (FFA), spectral-domain OCT of macula, widefield fundus imaging
- Systemic assessment: HbA1c, blood pressure, lipid profile, renal function (as diabetes affects multiple organs)
- For anti-VEGF injections: topical anaesthetic and antiseptic (povidone-iodine) prepared; injection given at the pars plana with a 30-gauge needle
- For PRP laser: pupil dilated; laser delivered through a wide-field contact lens in 1–3 sessions
- For vitrectomy: pre-operative anti-VEGF injection at day 7; vitrectomy performed under local anaesthesia with sedation
- Intraoperative membrane peeling and retinal flattening; laser endophotocoagulation to seal retinal breaks and treat ischaemia
- Gas or silicone oil tamponade as required; ports sealed; shield applied
- Post-operative OCT and IOP monitoring; anti-VEGF injections continued for DMO after surgery
Cost Comparison Worldwide
Country — Range — Savings
--- — --- — ---
USA — $2,000 – $8,000 per injection series — Save up to 85%
UK — £1,500 – £5,000 per injection series — Save up to 80%
UAE — $1,500 – $5,000 per injection series — Save up to 65%
India (anti-VEGF) — $300 – $1,000 per injection — Best value
India (vitrectomy) — $1,500 – $3,500 — Best value
Anti-VEGF injections in the USA cost $1,500–$2,000 per injection for ranibizumab or aflibercept; bevacizumab is $50–$100 per injection off-label. In India, ranibizumab costs $250–$400 per injection and bevacizumab (compounded for intravitreal use) costs $25–$50 per injection — making the annual treatment cost (6–8 injections per year) approximately $200–$3,000 in India versus $6,000–$15,000 in the USA.
Laser photocoagulation (PRP) in India costs $200–$500 per session (1–3 sessions for full PRP) compared to $1,500–$3,000 per session in the USA. Vitrectomy for diabetic complications in India costs $1,500–$3,500 compared to $8,000–$18,000 in the USA.
For international patients requiring ongoing treatment (multiple injection courses), India offers a particularly significant cost advantage. GAF Healthcare can coordinate treatment plans that interweave visits to India for injection courses with monitoring by a local ophthalmologist at home, minimising the number of trips required while ensuring treatment continuity.
Recovery & Follow-up
Anti-VEGF injections require only 24–48 hours of relative rest. The eye may be mildly sore or gritty for a day; vision may fluctuate slightly for a few days after injection. Most patients can return to normal activities the day after injection. The main restriction is to avoid swimming, rubbing the eye, and dusty environments for 48 hours.
Laser photocoagulation sessions cause some discomfort and photophobia for a few hours. Vision may be slightly reduced for a day, and peripheral vision is sometimes subtly reduced (a known side effect of PRP). Night vision is occasionally slightly reduced after extensive PRP. Most patients can drive themselves home after laser (if the pupil-dilating drops have fully worn off) and resume normal activities the same day.
Vitrectomy recovery follows the same course as retinal detachment vitrectomy — significant improvement in vision over weeks to months as haemorrhage clears and the retina heals. Tractional detachments that have involved the macula may leave permanent central vision loss. Gas tamponade restrictions and no-fly precautions apply if gas was used (see the Retinal Detachment Treatment section for details).
Recovery Tips
- Maintain excellent blood glucose control — the single most important factor in stopping retinopathy progression
- Keep blood pressure and cholesterol well controlled — hypertension and hyperlipidaemia significantly worsen diabetic retinal disease
- Attend every scheduled anti-VEGF injection appointment — skipping injections allows the oedema or neovascularisation to return
- Have your retina reviewed at least annually (or every 6 months if you have moderate-to-severe NPDR or recently treated PDR)
- Do not smoke — smoking significantly accelerates diabetic vascular damage in the eye and throughout the body
- Report any sudden visual change or new floaters immediately — these may indicate a vitreous haemorrhage or retinal detachment requiring urgent intervention
- Carry a copy of your retinal reports and OCT images when you travel — your local ophthalmologist will need these to monitor progress
Risks & Complications
Anti-VEGF injections are safe, with a very low rate of serious complications: endophthalmitis (eye infection) occurs in approximately 1 in 1,000–3,000 injections at carefully managed centres; elevated IOP after injection is common in the first few hours and rarely persistent; subconjunctival haemorrhage (bruising on the white of the eye) is common and harmless. Rare systemic cardiovascular events (stroke, heart attack) have been reported with anti-VEGF agents at very low rates, but as diabetics already have elevated cardiovascular risk, this is an important consideration for patients with recent cardiovascular events.
PRP laser risks include permanent reduction of peripheral visual field (most patients notice no functional impact at moderate PRP doses; extensive PRP can cause significant field loss), reduction in night vision, worsening of macular oedema in the short term (macular oedema should ideally be treated before or concurrently with PRP), and occasionally inadvertent foveal burns.
Vitrectomy risks are similar to those described in the Retinal Detachment Treatment section and include cataract acceleration (nearly universal in phakic eyes within 1–2 years), elevated IOP, recurrent haemorrhage, re-detachment, and infection.
Why GAF Healthcare
GAF Healthcare connects diabetic eye disease patients with India's most experienced vitreoretinal and medical retina teams — specialists who manage high volumes of diabetic retinopathy and maintain the full spectrum of treatment capability from anti-VEGF injections through to complex vitreoretinal surgery. We help patients design a sustainable long-term treatment plan that uses visits to India for higher-cost procedures (vitrectomy, ICO assessment, angiography) while coordinating anti-VEGF injection schedules that can be partially maintained by a local ophthalmologist at home.
Our coordinators liaise directly with your home diabetologist and ophthalmologist to ensure seamless communication. All patients receive a comprehensive retinal assessment report, OCT image library, and personalised monitoring protocol to take home, ensuring that the investment in treatment in India translates into long-term vision preservation.
Frequently Asked Questions
Can diabetic retinopathy be reversed?
Early to moderate non-proliferative diabetic retinopathy (NPDR) can stabilise or partially regress with excellent blood glucose control (HbA1c below 7%), blood pressure control, and lipid management — without any eye-specific treatment. Diabetic macular oedema almost always improves with anti-VEGF injections, and many patients regain several lines of vision. Proliferative diabetic retinopathy (PDR) can be stabilised and the new blood vessels regressed with PRP laser and/or anti-VEGF injections. However, structural damage to the retina from long-standing ischaemia, retinal scarring, or macular damage is irreversible.
How many anti-VEGF injections will I need?
For diabetic macular oedema (DMO), most published trials and clinical practice protocols start with a loading phase of 3–6 monthly injections, followed by maintenance injections every 1–3 months on an as-needed or treat-and-extend schedule. Many patients need ongoing injections for years to maintain the benefit; some achieve long-term remission after 1–2 years of treatment. Your retinal specialist will determine your injection frequency based on your OCT response. On average, patients with DMO receive 7–9 injections in the first year and fewer in subsequent years as the disease is controlled.
I have had a sudden blurring of vision and think I may have a vitreous haemorrhage. What should I do?
A sudden shower of new floaters, red or dark shadows in the vision, or sudden severe vision loss in a diabetic patient may indicate a vitreous haemorrhage from proliferative diabetic retinopathy. This requires urgent ophthalmic review — ideally the same day — to confirm the diagnosis, assess whether the retina is detached, and plan treatment. If you are in India, go to the nearest emergency eye department immediately. If you are planning to come to India for treatment, contact GAF Healthcare for an emergency referral pathway.
Is laser or anti-VEGF better for diabetic retinopathy?
For diabetic macular oedema (DMO) affecting the fovea (centre-involving DMO), anti-VEGF injections are the current gold-standard first-line treatment — large randomised trials have shown superior visual outcomes compared to laser. For proliferative diabetic retinopathy (PDR), panretinal photocoagulation (PRP) laser is the traditional and still commonly used treatment, but anti-VEGF injections are increasingly used as an alternative (or adjunct) that avoids the peripheral field loss associated with PRP. Most patients with both DMO and PDR receive a combination of anti-VEGF and laser tailored to their specific disease pattern.
Can I be screened for diabetic retinopathy during my trip to India?
Absolutely. Comprehensive diabetic eye screening — digital fundus photography, spectral-domain OCT of the macula, fluorescein angiography (if indicated), and a full vitreoretinal examination — can be completed within a single clinic visit (2–3 hours) at any of GAF Healthcare's partner eye centres. If you have diabetes and have not had a retinal examination in the past 12 months, GAF Healthcare strongly recommends including a retinal screen in your medical tourism itinerary. Early detection of retinopathy at a treatable stage can prevent future blindness.